EXPLORING THE ANTINOCICEPTIVE AND ANTIDEPRESSANT POTENTIAL OF 3,3-DIBROMOFLAVANONE: A NOVEL THERAPEUTIC CANDIDATE FOR PAIN MANAGEMENT WITH IMPROVED SAFETY PROFILE OVER MORPHINE

NATALIA COLETTIS; JOSEFINA HIGGS; CRISTINA WASOWSKI; VALENTINA PASTORE; MARIEL MARDER

Mar del Plata

Congreso; REUNIÓN CONJUNTA SAIC SAB AAFE AACYTAL 2023; 2023

In the search for lead compounds with reduced side effects comparedto opioids, the synthetic phytochemical 3,3-dibromoflavanone(3,3-DBF) emerged as a promising pain management candidate.3,3-DBF displayed dose-dependent antinociceptive activity mediatedby the μ-opioid receptor in central and peripheral pathways.Unlike morphine (MOR), chronic 3,3-DBF administration demonstratedantinociceptive effects without inducing tolerance, impactinglocomotor activity, motor coordination, or causing constipation. Thisstudy aimed to explore 3,3-DBF effects in mice, focusing on dependenceand depression, a typical pain comorbidity. The dependenceeffect was examined in mice divided into three group treatments,receiving 3,3-DBF, MOR, or vehicle twice daily for three consecutivedays, with doses doubling daily to reach 60 mg/kg (MOR) and 100mg/kg (3,3-DBF). On day four, half of each group treatment receivedeither naltrexone (1 mg/kg), to induce withdrawal syndrome, or salineas a control. Withdrawal signs induced by 3,3-DBF were assessedusing the Gellert-Holtzman scale. Two-way ANOVA followedby Dunnet indicated 3,3-DBF didn’t elicit withdrawal signs (P>0.05)comparable to MOR (P